Literature DB >> 22154898

How informative are open-label studies for youth with bipolar disorder? A meta-analysis comparing open-label versus randomized, placebo-controlled clinical trials.

Joseph Biederman1, Carter R Petty, K Yvonne Woodworth, Alexandra Lomedico, Katherine B O'Connor, Janet Wozniak, Stephen V Faraone.   

Abstract

OBJECTIVE: To examine the informativeness of open-label trials toward predicting results in subsequent randomized, placebo-controlled clinical trials of psychopharmacologic treatments for pediatric bipolar disorder. DATA SOURCES: We searched journal articles through PubMed at the National Library of Medicine using bipolar disorder, mania, pharmacotherapy, treatment and clinical trial as keywords. This search was supplemented with scientific presentations at national and international scientific meetings and submitted manuscripts from our group. STUDY SELECTION: Selection criteria included (1) enrollment of children diagnosed with DSM-IV bipolar disorder; (2) prospective assessment of at least 3 weeks; (3) monotherapy of a pharmacologic treatment for bipolar disorder; (4) use of a randomized placebo-controlled design or an open-label design for the same therapeutic compound; and (5) repeated use of the Young Mania Rating Scale (YMRS) as an outcome. DATA EXTRACTION: The following information and data were extracted from 14 studies: study design, name of medication, class of medication, dose of medication, sample size, age, sex, trial length, and YMRS mean and standard deviation baseline and follow-up scores.
RESULTS: For both study designs, the pooled effect size was statistically significant (open-label studies, z = 8.88, P < .001; randomized placebo-controlled studies, z = 13.75, P < .001), indicating a reduction in the YMRS from baseline to endpoint in both study designs. In a meta-analysis regression, study design was not a significant predictor of mean change in the YMRS.
CONCLUSIONS: We found similarities in the treatment effects between open-label and randomized placebo-controlled studies in youth with bipolar disorder indicating that open-label studies are useful predictors of the potential safety and efficacy of a given compound in the treatment of pediatric bipolar disorder. © Copyright 2012 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22154898     DOI: 10.4088/JCP.10m06490

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  4 in total

1.  A Randomized, Double-Blind, Controlled Trial of Lithium Versus Quetiapine for the Treatment of Acute Mania in Youth with Early Course Bipolar Disorder.

Authors:  Luis R Patino; Christina C Klein; Jeffrey R Strawn; Thomas J Blom; Maxwell J Tallman; Caleb M Adler; Jeffrey A Welge; Melissa P DelBello
Journal:  J Child Adolesc Psychopharmacol       Date:  2021-09-14       Impact factor: 3.031

2.  A prospective open-label trial of paliperidone monotherapy for the treatment of bipolar spectrum disorders in children and adolescents.

Authors:  Gagan Joshi; Carter Petty; Janet Wozniak; Stephen V Faraone; Andrea E Spencer; K Yvonne Woodworth; Rachel Shelley-Abrahamson; Hannah McKillop; Stephannie L Furtak; Joseph Biederman
Journal:  Psychopharmacology (Berl)       Date:  2013-02-09       Impact factor: 4.530

3.  Why Systematic Review rather than Narrative Review?

Authors:  Chi-Un Pae
Journal:  Psychiatry Investig       Date:  2015-07-06       Impact factor: 2.505

Review 4.  A Meta-Analysis Comparing Open-Label versus Placebo-Controlled Clinical Trials for Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: Lessons and Promises.

Authors:  Chi-Un Pae; Ho-Jun Seo; Boung Chul Lee; Jeong-Ho Seok; Hong Jin Jeon; Jong-Woo Paik; Kyung-Phil Kwak; Byung-Joo Ham; Changsu Han; Soo-Jung Lee
Journal:  Psychiatry Investig       Date:  2014-10-20       Impact factor: 2.505

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.